Nimustine

Cat. No.: HY-13703: FAQs
Data Sheet Handling Instructions Technical Support

Nimustine is a nitrosourea alkylating agent. Nimustine induces cell apoptosis, and activates DNA damage response and MAPK signaling. Nimustine shows anti-cancer effects, it can be used for the research of cancer.

At equivalent molar concentrations, both the salt and free forms of a compound exhibit comparable biological activity. Nevertheless, the salt form (Nimustine hydrochloride) usually boasts enhanced water solubility and stability.

For research use only. We do not sell to patients.

Nimustine Chemical Structure

CAS No. : 42471-28-3

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Nimustine:

Nimustine hydrochloride Get quote

1 Publications Citing Use of MCE Nimustine

•ACS Appl Mater Interfaces. 2023 May 26. [Abstract]

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
SF-126	IC₅₀	310 μM Compound: ACNU	Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay in presence of O6-BG	[PMID: 27041398]
SF-126	IC₅₀	320 μM Compound: ACNU	Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay Cytotoxicity against human SF126 cells expressing low level of AGT assessed as cell survival after 24 hrs by CCK8 assay	[PMID: 27041398]
SF-126	IC₅₀	360 μM Compound: ACNU	Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability pretreated with O6-BG for 2 hrs followed by addition of compound measured after 24 hrs by CCK8 assay	[PMID: 28197307]
SF-126	IC₅₀	450 μM Compound: ACNU	Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay Cytotoxicity against AGT-deficient human SF126 cells assessed as reduction in cell viability measured after 24 hrs by CCK8 assay	[PMID: 28197307]
U-87MG ATCC	IC₅₀	0.84 μM Compound: Nimustine	Cytotoxicity against human U87MG cells after 72 hrs by MTT assay Cytotoxicity against human U87MG cells after 72 hrs by MTT assay	[PMID: 20184290]

In Vitro

Nimustine (50 μM; 72-120 h) causes cell death by inducing cell apoptosis^[1].
Nimustine (50 μM; 24-96 h) activates the DNA damage response pathway^[1].
Nimustine (50 μM; 24-120 h) activates MAPK signaling in glioma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:	LN-229 cell line
Concentration:	50 μM
Incubation Time:	72-120 hours
Result:	Time-dependently induced apoptosis.

Western Blot Analysis^[1]

Cell Line:	LN-229 and glioma cell lines
Concentration:	50 μM
Incubation Time:	24-120 hours
Result:	Induced cleavage of caspase-8 and -9 and the effector caspase-3. Increased phosphorylation of ERK kinase and H2AX. Decreased phosphorylation of JNK

In Vivo

Nimustine (15 four times a week and 30 mg/kg twice with an interval of 2 weeks; i.v.) effectively inhibits tumor growth and the higher dose is more effective^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female C3H/HeN mice with solid FM3A tumors^[2]
Dosage:	15 and 30 mg/kg
Administration:	Intravenous injection; 15 (4 times a week) and 30 mg/kg (twice with an interval of 2 weeks)
Result:	The intermittent large-dose injections resulted in better inhibition of tumor growth than did the fractionated small-dose injections.

Clinical Trial

Molecular Weight

272.69

Formula

C₉H₁₃ClN₆O₂

CAS No.

42471-28-3

SMILES

O=C(NCC1=CN=C(C)N=C1N)N(CCCl)N=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Tomicic MT, et al. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM. Oncotarget. 2015 Oct 20;6(32):33755-68. [Content Brief]

[2]. Shimizu F, et al. Effects of combined treatment with nimustine hydrochloride and radiation on solid FM3A tumor in mice. Jpn J Cancer Res. 1987 Jul;78(7):756-62. [Content Brief]

Nimustine Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nimustine42471-28-3Apoptosisnitrosourea alkylatingapoptosisDNA damageMAPKanti-cancerLN-229gliomamiceFM3AInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *